Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2022-04-07 Declaration of Voting R…
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled "STATEMENT OF TOTAL VOTING RIGHTS AND SHARES FORMING THE COMPANY'S SHARE CAPITAL" and references French regulatory codes (Articles L.233-8 II of the French Commercial Code and 223-16 of the AMF General Regulations). It provides a precise table detailing the number of outstanding shares and total voting rights (gross and net) as of a specific date (March 31, 2022). This content directly relates to the official disclosure of voting rights and share capital structure, which is a specific regulatory announcement. Among the provided codes, this type of disclosure is best categorized as a notification regarding share capital structure or a general regulatory filing. Since there is no specific code for 'Total Voting Rights Statement', and it is a formal regulatory disclosure, it fits best under 'Declaration of Voting Results & Voting Rights Announcements' (DVA) if it were related to a vote outcome, or as a general regulatory filing (RNS). However, given the precise nature of reporting voting rights, DVA is the most specific fit, even if it's a routine update rather than post-meeting results. If DVA is strictly for post-meeting results, then RNS is the fallback. Reviewing the definitions, DVA is for 'Official results from shareholder votes at any general meeting'. This document is a routine update of total voting rights, not the result of a specific vote. Therefore, it falls under the general regulatory announcement category, RNS, as it is a mandatory disclosure that doesn't fit the other specific categories like DIV, SHA, or DIRS.
2022-04-07 English
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of March 31, 2022. This content directly corresponds to regulatory requirements for disclosing changes in total share capital and voting rights, which is often captured under Major Shareholding Notification (MRQ) or a specific regulatory disclosure category. Since the core content is a mandatory monthly disclosure about the total number of shares and voting rights, it fits best under the 'Major Shareholding Notification' (MRQ) category, which covers notifications of changes in significant share ownership levels, although this specific filing is about the total capital base, which is a prerequisite for threshold monitoring. Given the options, MRQ is the closest fit for mandatory capital structure disclosures related to shareholder rights/ownership reporting, though 'RNS' (Regulatory Filings) is also plausible if MRQ is strictly interpreted as crossing thresholds rather than routine updates. However, the specific nature of reporting total voting rights monthly aligns closely with the scope of disclosures related to share ownership structure.
2022-04-07 French
Inside Information / Other news releases
Earnings Release Classification · 95% confidence The document is explicitly titled "NANOBIOTIX PROVIDES BUSINESS UPDATE AND REPORTS FULL YEAR 2021 FINANCIAL RESULTS" and contains detailed financial figures for the year ended December 31, 2021, including Revenue, R&D Expenses, SG&A Expenses, and Net Loss. This content structure strongly indicates a comprehensive annual financial disclosure. Although it is presented as a press release, the depth of the financial reporting aligns with the content expected in an Annual Report (10-K) or a detailed Earnings Release/Interim Report. Since it covers the *full year* results and includes a note referencing the statutory auditors' work on the 2021 financial statements and the forthcoming 2021 annual report on Form 20-F, it functions as the primary disclosure of the annual results. Given the options, 'ER' (Earnings Release) is the closest fit for a press release announcing annual results, but '10-K' is the formal regulatory filing for full-year results. However, this document is a press release summarizing the results and operational updates, which is the typical format for an Earnings Release (ER). It is not a comprehensive 10-K, nor is it just a short announcement (RPA). It contains the core financial data summary. I will classify it as an Earnings Release (ER) as it is a press release format detailing period results. FY 2021
2022-03-30 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 99% confidence The document is titled "NANOBIOTIX FAIT LE POINT SUR SES ACTIVITÉS ET PUBLIE SES RÉSULTATS FINANCIERS POUR L'ANNÉE 2021" (NANOBIOTIX PROVIDES AN UPDATE ON ITS ACTIVITIES AND PUBLISHES ITS FINANCIAL RESULTS FOR THE YEAR 2021). It contains detailed financial figures for the fiscal year ended December 31, 2021, including revenue, R&D expenses, SG&A, and net loss. It also discusses clinical trial progress and operational updates. The text explicitly mentions that the financial data is from the consolidated accounts for the year ended December 31, 2021, and notes that the auditors' report is pending, which will be included in the 'document d'enregistrement universel 2021' and the 'rapport annuel « Form 20-F »'. The presence of comprehensive annual financial data, operational review, and the reference to the upcoming 20-F strongly suggests this is the company's Annual Report disclosure, even if presented as a press release summarizing the full filing. Since the document length is substantial (28,492 chars) and it contains the full financial details rather than just an announcement of publication, it classifies as the Annual Report (10-K equivalent for non-US filers reporting under US standards, or the comprehensive annual filing). FY 2021
2022-03-30 French
Inside Information / Other news releases
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "STATEMENT OF TOTAL VOTING RIGHTS AND SHARES FORMING THE COMPANY'S SHARE CAPITAL" and explicitly references French Commercial Code articles and regulations from the Autorité des Marchés Financiers (AMF). It provides a table detailing the number of shares outstanding and the total number of voting rights (gross and net) as of a specific date (February 28, 2022). This type of mandatory disclosure regarding the total number of voting rights is a specific regulatory announcement. It does not fit the definitions for an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or a general regulatory filing (RNS). It is most closely related to announcements concerning share capital structure or voting rights, which aligns best with 'Declaration of Voting Results & Voting Rights Announcements' (DVA), as it reports the basis for future shareholder votes, or potentially a specific regulatory filing. Given the explicit focus on 'Total voting rights' and the regulatory context, DVA is the most precise fit, although it is not a result of a vote, but the underlying data for voting. Since DVA specifically covers 'Voting Rights Announcements', this is the best match over the general RNS.
2022-03-08 English
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and Règlement Général de l'Autorité des Marchés Financiers - AMF) and provides a table detailing the total number of shares and voting rights as of a specific date (February 28, 2022). This content directly relates to mandatory disclosures regarding changes in the total number of shares and voting rights, which is a specific type of regulatory filing often related to capital structure or major shareholding notifications, but most precisely fits the category for tracking significant ownership changes or capital structure updates. Reviewing the definitions: - 'SHA' (Share Issue/Capital Change) is for announcements regarding new share issues, stock splits, or other capital changes. - 'MRQ' (Major Shareholding Notification) is for notification of changes in significant share ownership levels (crossing thresholds). Since this document reports the *total* capital structure and voting rights, it is a routine disclosure mandated by regulators, often preceding or accompanying major shareholder notifications or capital changes. However, the core content is the monthly count of shares and voting rights. This type of mandatory monthly disclosure in France is often classified under general regulatory filings or specific capital structure updates. Given the options, 'SHA' (Share Issue/Capital Change) covers the underlying data (total shares/capital), and 'MRQ' covers the context (voting rights thresholds). Since the document is a formal, mandated disclosure of the total share count, it is most closely aligned with reporting on the capital structure itself. In many contexts, this specific monthly report is a precursor or component of disclosures related to capital changes or major holdings. Given the options, 'SHA' is a strong fit as it relates to the capital structure, but 'MRQ' relates to the voting rights thresholds mentioned. Since the document explicitly states it is reporting the total number of shares and voting rights, which is the basis for crossing thresholds, and it is a formal regulatory communication, it is best classified as a general regulatory filing or one related to share capital. In the context of the provided definitions, 'SHA' (Share Issue/Capital Change) is the closest fit for a formal report on the total number of shares comprising the capital, even if it's a routine update rather than a specific issuance announcement. However, if we consider the context of French market practice, these reports are often filed when thresholds are crossed, making 'MRQ' relevant. Since this is a routine monthly report, and not an announcement of a specific transaction or threshold breach, 'SHA' (Capital structure update) or 'RNS' (General regulatory filing) are the best candidates. Given the highly specific nature of the data (total shares and voting rights), and the fact that it is a formal regulatory communication, 'RNS' (Regulatory Filings - fallback) is appropriate if it doesn't fit perfectly elsewhere. Let's re-evaluate 'SHA'. It covers 'other capital changes'. A change in the total share count (even if static this month) is a capital structure report. Let's check 'MRQ' again: 'Notification of changes in significant share ownership levels (crossing thresholds)'. This report provides the data needed for that. Given the explicit focus on 'droits de vote' (voting rights), 'MRQ' is highly relevant. However, since this is a routine monthly report of the *total* capital, and not an announcement of a *change* in ownership crossing a threshold, 'SHA' (Capital structure update) or 'RNS' is safer. I will lean towards 'RNS' as the most accurate fallback for a routine, mandated monthly regulatory disclosure that doesn't perfectly match the transactional nature of SHA or MRQ. Revisiting the definitions: This is a mandatory disclosure of the total share count and voting rights, often required by AMF rules regardless of threshold breaches. This fits best under a general regulatory filing category if a more specific one isn't perfect. 'RNS' is the general regulatory filing fallback. I will assign RNS.
2022-03-08 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.